340 related articles for article (PubMed ID: 18652679)
1. Comparison of human B cell activation by TLR7 and TLR9 agonists.
Hanten JA; Vasilakos JP; Riter CL; Neys L; Lipson KE; Alkan SS; Birmachu W
BMC Immunol; 2008 Jul; 9():39. PubMed ID: 18652679
[TBL] [Abstract][Full Text] [Related]
2. Human and rhesus plasmacytoid dendritic cell and B-cell responses to Toll-like receptor stimulation.
Gujer C; Sundling C; Seder RA; Karlsson Hedestam GB; Loré K
Immunology; 2011 Nov; 134(3):257-69. PubMed ID: 21977996
[TBL] [Abstract][Full Text] [Related]
3. TLR9-Activating CpG-B ODN but Not TLR7 Agonists Triggers Antibody Formation to Factor IX in Muscle Gene Transfer.
Butterfield JSS; Biswas M; Shirley JL; Kumar SRP; Sherman A; Terhorst C; Ling C; Herzog RW
Hum Gene Ther Methods; 2019 Jun; 30(3):81-92. PubMed ID: 31140323
[TBL] [Abstract][Full Text] [Related]
4. TLR1/2, TLR7, and TLR9 signals directly activate human peripheral blood naive and memory B cell subsets to produce cytokines, chemokines, and hematopoietic growth factors.
Agrawal S; Gupta S
J Clin Immunol; 2011 Feb; 31(1):89-98. PubMed ID: 20821041
[TBL] [Abstract][Full Text] [Related]
5. pDC Activation by TLR7/8 Ligand CL097 Compared to TLR7 Ligand IMQ or TLR9 Ligand CpG.
Wu J; Li S; Li T; Lv X; Zhang M; Zang G; Qi C; Liu YJ; Xu L; Chen J
J Immunol Res; 2019; 2019():1749803. PubMed ID: 31093508
[TBL] [Abstract][Full Text] [Related]
6. Toll-like receptor 7 and 9 defects in common variable immunodeficiency.
Yu JE; Knight AK; Radigan L; Marron TU; Zhang L; Sanchez-Ramón S; Cunningham-Rundles C
J Allergy Clin Immunol; 2009 Aug; 124(2):349-56, 356.e1-3. PubMed ID: 19592080
[TBL] [Abstract][Full Text] [Related]
7. TLR9 agonist, but not TLR7/8, functions as an adjuvant to diminish FI-RSV vaccine-enhanced disease, while either agonist used as therapy during primary RSV infection increases disease severity.
Johnson TR; Rao S; Seder RA; Chen M; Graham BS
Vaccine; 2009 May; 27(23):3045-52. PubMed ID: 19428918
[TBL] [Abstract][Full Text] [Related]
8. TLR7- and TLR9-responsive human B cells share phenotypic and genetic characteristics.
Simchoni N; Cunningham-Rundles C
J Immunol; 2015 Apr; 194(7):3035-44. PubMed ID: 25740945
[TBL] [Abstract][Full Text] [Related]
9. Suppression of B-cell activation and IgE, IgA, IgG1 and IgG4 production by mammalian telomeric oligonucleotides.
Sackesen C; van de Veen W; Akdis M; Soyer O; Zumkehr J; Ruckert B; Stanic B; Kalaycı O; Alkan SS; Gursel I; Akdis CA
Allergy; 2013; 68(5):593-603. PubMed ID: 23480796
[TBL] [Abstract][Full Text] [Related]
10. Chemokine, cytokine and type I interferon production induced by Toll-like receptor activation in common variable immune deficiency.
Lollo C; de Moraes Vasconcelos D; Oliveira LMDS; Domingues R; Carvalho GC; Duarte AJDS; Sato MN
Clin Immunol; 2016 Aug; 169():121-127. PubMed ID: 27392462
[TBL] [Abstract][Full Text] [Related]
11. Oligodeoxynucleotides differentially modulate activation of TLR7 and TLR8 by imidazoquinolines.
Gorden KK; Qiu X; Battiste JJ; Wightman PP; Vasilakos JP; Alkan SS
J Immunol; 2006 Dec; 177(11):8164-70. PubMed ID: 17114492
[TBL] [Abstract][Full Text] [Related]
12. IFN-alpha amplifies human naive B cell TLR-9-mediated activation and Ig production.
Giordani L; Sanchez M; Libri I; Quaranta MG; Mattioli B; Viora M
J Leukoc Biol; 2009 Aug; 86(2):261-71. PubMed ID: 19401392
[TBL] [Abstract][Full Text] [Related]
13. Quantitative expression of toll-like receptor 1-10 mRNA in cellular subsets of human peripheral blood mononuclear cells and sensitivity to CpG oligodeoxynucleotides.
Hornung V; Rothenfusser S; Britsch S; Krug A; Jahrsdörfer B; Giese T; Endres S; Hartmann G
J Immunol; 2002 May; 168(9):4531-7. PubMed ID: 11970999
[TBL] [Abstract][Full Text] [Related]
14. Negative regulation of TLR9-mediated IFN-alpha induction by a small-molecule, synthetic TLR7 ligand.
Marshall JD; Heeke DS; Gesner ML; Livingston B; Van Nest G
J Leukoc Biol; 2007 Sep; 82(3):497-508. PubMed ID: 17565046
[TBL] [Abstract][Full Text] [Related]
15. B cell TLR1/2, TLR4, TLR7 and TLR9 interact in induction of class switch DNA recombination: modulation by BCR and CD40, and relevance to T-independent antibody responses.
Pone EJ; Lou Z; Lam T; Greenberg ML; Wang R; Xu Z; Casali P
Autoimmunity; 2015 Feb; 48(1):1-12. PubMed ID: 25536171
[TBL] [Abstract][Full Text] [Related]
16. Bruton's tyrosine kinase regulates TLR9 but not TLR7 signaling in human plasmacytoid dendritic cells.
Wang J; Lau KY; Jung J; Ravindran P; Barrat FJ
Eur J Immunol; 2014 Apr; 44(4):1130-6. PubMed ID: 24375473
[TBL] [Abstract][Full Text] [Related]
17. Natural and synthetic TLR7 ligands inhibit CpG-A- and CpG-C-oligodeoxynucleotide-induced IFN-alpha production.
Berghöfer B; Haley G; Frommer T; Bein G; Hackstein H
J Immunol; 2007 Apr; 178(7):4072-9. PubMed ID: 17371961
[TBL] [Abstract][Full Text] [Related]
18. HIV-1 gp120 impairs the induction of B cell responses by TLR9-activated plasmacytoid dendritic cells.
Chung NP; Matthews K; Klasse PJ; Sanders RW; Moore JP
J Immunol; 2012 Dec; 189(11):5257-65. PubMed ID: 23100517
[TBL] [Abstract][Full Text] [Related]
19. Transcriptional networks in plasmacytoid dendritic cells stimulated with synthetic TLR 7 agonists.
Birmachu W; Gleason RM; Bulbulian BJ; Riter CL; Vasilakos JP; Lipson KE; Nikolsky Y
BMC Immunol; 2007 Oct; 8():26. PubMed ID: 17935622
[TBL] [Abstract][Full Text] [Related]
20. The dysfunctional innate immune response triggered by Toll-like receptor activation is restored by TLR7/TLR8 and TLR9 ligands in cutaneous lichen planus.
Domingues R; de Carvalho GC; da Silva Oliveira LM; Futata Taniguchi E; Zimbres JM; Aoki V; da Silva Duarte AJ; Sato MN
Br J Dermatol; 2015 Jan; 172(1):48-55. PubMed ID: 24976336
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
